[go: up one dir, main page]

DK3317300T3 - Bispecifikke antistoffer til anvendelse i kræftimmunterapi - Google Patents

Bispecifikke antistoffer til anvendelse i kræftimmunterapi Download PDF

Info

Publication number
DK3317300T3
DK3317300T3 DK16744669.9T DK16744669T DK3317300T3 DK 3317300 T3 DK3317300 T3 DK 3317300T3 DK 16744669 T DK16744669 T DK 16744669T DK 3317300 T3 DK3317300 T3 DK 3317300T3
Authority
DK
Denmark
Prior art keywords
cancer
bispecific antibodies
hour therapy
therapy
hour
Prior art date
Application number
DK16744669.9T
Other languages
English (en)
Inventor
Mariangela Figini
Alessandro Satta
Alessandro Massimo Gianni
Nicola Massimo Di
Original Assignee
Fondazione Irccs Istituto Naz Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione Irccs Istituto Naz Dei Tumori filed Critical Fondazione Irccs Istituto Naz Dei Tumori
Application granted granted Critical
Publication of DK3317300T3 publication Critical patent/DK3317300T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626Diabody or triabody
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK16744669.9T 2015-07-01 2016-07-01 Bispecifikke antistoffer til anvendelse i kræftimmunterapi DK3317300T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15174741.7A EP3112381A1 (en) 2015-07-01 2015-07-01 Bispecific antibodies for use in cancer immunotherapy
PCT/EP2016/065577 WO2017001681A1 (en) 2015-07-01 2016-07-01 Bispecific antibodies for use in cancer immunotherapy

Publications (1)

Publication Number Publication Date
DK3317300T3 true DK3317300T3 (da) 2021-02-01

Family

ID=53498900

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16744669.9T DK3317300T3 (da) 2015-07-01 2016-07-01 Bispecifikke antistoffer til anvendelse i kræftimmunterapi

Country Status (18)

Country Link
US (1) US10813995B2 (da)
EP (2) EP3112381A1 (da)
JP (1) JP6876006B2 (da)
KR (1) KR20180053639A (da)
CN (1) CN108602886B (da)
AU (1) AU2016285118B2 (da)
CA (1) CA2990517C (da)
CY (1) CY1123839T1 (da)
DK (1) DK3317300T3 (da)
ES (1) ES2848391T3 (da)
HR (1) HRP20210152T1 (da)
HU (1) HUE053128T2 (da)
LT (1) LT3317300T (da)
PL (1) PL3317300T3 (da)
PT (1) PT3317300T (da)
RS (1) RS61444B1 (da)
SI (1) SI3317300T1 (da)
WO (1) WO2017001681A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107417792B (zh) * 2017-08-29 2020-07-03 天津医科大学总医院 抗cd40-her2双特异性单链抗体及其在制备抗肿瘤药物中的应用
WO2019098563A1 (ko) 2017-11-20 2019-05-23 주식회사 엘지화학 회전식 디스크 시스템을 활용한 중금속 정성 및 정량 분석 디바이스 및 분석 방법
CA3104274A1 (en) 2018-05-10 2019-11-14 Mirabiologics Inc. Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides
WO2020227431A1 (en) * 2019-05-06 2020-11-12 Brown University Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells
CN114573705B (zh) * 2022-03-17 2024-05-14 杭州师范大学 特异性启动抗乙型肝炎病毒t细胞免疫的双特异性抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
MXPA02010011A (es) * 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
JP3803790B2 (ja) * 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
SG186656A1 (en) * 2007-12-14 2013-01-30 Bristol Myers Squibb Co Binding molecules to the human ox40 receptor
EP2684896A1 (en) * 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
TN2016000525A1 (en) * 2014-05-29 2018-04-04 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
SG11201706024YA (en) * 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains

Also Published As

Publication number Publication date
CN108602886B (zh) 2021-10-15
WO2017001681A8 (en) 2018-03-29
JP6876006B2 (ja) 2021-05-26
RS61444B1 (sr) 2021-03-31
CA2990517C (en) 2023-08-29
HRP20210152T1 (hr) 2021-03-19
US20180250396A1 (en) 2018-09-06
LT3317300T (lt) 2021-05-10
SI3317300T1 (sl) 2021-04-30
JP2018525347A (ja) 2018-09-06
WO2017001681A1 (en) 2017-01-05
AU2016285118B2 (en) 2021-12-16
KR20180053639A (ko) 2018-05-23
CY1123839T1 (el) 2022-05-27
HUE053128T2 (hu) 2021-06-28
AU2016285118A9 (en) 2019-08-01
EP3112381A1 (en) 2017-01-04
EP3317300A1 (en) 2018-05-09
ES2848391T3 (es) 2021-08-09
CN108602886A (zh) 2018-09-28
EP3317300B1 (en) 2020-11-18
US10813995B2 (en) 2020-10-27
PT3317300T (pt) 2021-02-04
CA2990517A1 (en) 2017-01-05
AU2016285118A1 (en) 2018-02-22
PL3317300T3 (pl) 2021-05-31

Similar Documents

Publication Publication Date Title
CY2024021I2 (el) Bispecific t cell activating antigen binding molecules
IL283733A (en) Methods of cancer treatment using activated t cells
IL296080B1 (en) Method for treating cancer
ZA201703290B (en) Methods for tumor treatment using cd3xcd20 bispecific antibody
IL256760A (en) Human cd3 binding antibody
CL2018000370A1 (es) Nuevos anticuerpos anti-pd-1
IL255261A0 (en) Methods for treating cancer
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
HUE046505T2 (hu) Antitestkészítmények daganatkezelésre
DK3508502T3 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
PL3458052T3 (pl) Leczenie skojarzone nowotworu
EP3413927A4 (en) CANCER THERAPY
DK3386997T3 (da) Monomaleimid-funktionaliserede platinforbindelser til cancerterapi
DK3253208T3 (da) Kombinationsterapier til anvendelse i behandlingen af brystcancer
DK3317300T3 (da) Bispecifikke antistoffer til anvendelse i kræftimmunterapi
DK3344287T3 (da) Anti-survivin-antistoffer til cancerterapi
GB201509493D0 (en) Therapeutic antibody
TH1501006324A (th) การบำบัดมะเร็งด้วยไดไฮโดรพิแรซิโน-พิแรซีน
TH1501007353A (th) สารประกอบชนิดใหม่สำหรับการบำบัดโรคมะเร็ง